Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Stone A, Valdés-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL, Musgrove EA, Nicholson RI.

PLoS One. 2012;7(7):e40466. doi: 10.1371/journal.pone.0040466. Epub 2012 Jul 10.

3.

Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.

Badia E, Duchesne MJ, Semlali A, Fuentes M, Giamarchi C, Richard-Foy H, Nicolas JC, Pons M.

Cancer Res. 2000 Aug 1;60(15):4130-8.

4.

Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.

Li G, Zhang J, Jin K, He K, Zheng Y, Xu X, Wang H, Wang H, Li Z, Yu X, Teng X, Cao J, Teng L.

Mol Oncol. 2013 Jun;7(3):611-24. doi: 10.1016/j.molonc.2013.02.001. Epub 2013 Feb 26.

5.

Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.

Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.

Mol Cancer Res. 2008 Aug;6(8):1347-55. doi: 10.1158/1541-7786.MCR-07-2179.

6.

An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.

Huang L, Zhao S, Frasor JM, Dai Y.

PLoS One. 2011;6(7):e22274. doi: 10.1371/journal.pone.0022274. Epub 2011 Jul 15.

7.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

8.

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.

Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M.

J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):333-41.

PMID:
12361723
9.

Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.

Lin X, Li J, Yin G, Zhao Q, Elias D, Lykkesfeldt AE, Stenvang J, Brünner N, Wang J, Yang H, Bolund L, Ditzel HJ.

Breast Cancer Res. 2013 Dec 19;15(6):R119. doi: 10.1186/bcr3588.

10.

Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.

Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, Ahn SG, Yoon JH, Kang KW.

Breast Cancer Res Treat. 2011 Nov;130(1):73-83. doi: 10.1007/s10549-010-1304-2. Epub 2010 Dec 18.

PMID:
21170675
11.

DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells.

Singh KP, Treas J, Tyagi T, Gao W.

Cancer Lett. 2012 Mar;316(1):62-9. doi: 10.1016/j.canlet.2011.10.022. Epub 2011 Oct 23.

PMID:
22082530
12.

Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.

Pitta CA, Papageorgis P, Charalambous C, Constantinou AI.

Cancer Lett. 2013 Sep 1;337(2):167-76. doi: 10.1016/j.canlet.2013.05.031. Epub 2013 Jun 7.

PMID:
23752064
13.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

14.

Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells.

Putnik M, Zhao C, Gustafsson JÅ, Dahlman-Wright K.

Biochem Biophys Res Commun. 2012 Sep 14;426(1):26-32. doi: 10.1016/j.bbrc.2012.08.007. Epub 2012 Aug 10.

PMID:
22902638
15.
16.

Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.

Block M, Gründker C, Fister S, Kubin J, Wilkens L, Mueller MD, Hemmerlein B, Emons G, Günthert AR.

Int J Oncol. 2012 Nov;41(5):1845-54. doi: 10.3892/ijo.2012.1591. Epub 2012 Aug 21.

PMID:
22922893
17.

Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.

Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S.

Sci Transl Med. 2014 Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326.

19.

Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.

Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, Artemov D, Kowalski J, Carraway H, van Diest P, Raman V.

Oncogene. 2012 Jul 5;31(27):3223-34. doi: 10.1038/onc.2011.483. Epub 2011 Nov 7.

20.

Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.

Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M.

Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.

PMID:
19288272
Items per page

Supplemental Content

Write to the Help Desk